In January, we added 112 citations in DIDB, including 65 in vitro (with 12 articles published in January 2026) and 47 in vivo articles (with 37 articles published in January 2026).
4 NDAs and 3 BLAs approved by the FDA in November and December 2025, including depemokimab (EXDENSUR), doxecitine and doxribtimine (KYGEVVI), etripamil (CARDAMYST), lerodalcibep (LEROCHOL), plozasiran (REDEMPLO), sibeprenlimab (VOYXACT), and zoliflodacin (NUZOLVENCE) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.